Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nebivolol: Phase III data

In a 12-week, double-blind Phase III trial in 300 African American patients with stage

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE